Hosted on MSN
ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory
CEO John Tucker stated that "scPharmaceuticals is better positioned than at any point in our history" and emphasized the ongoing success of FUROSCIX, noting its expanding market penetration and ...
The MarketWatch News Department was not involved in the creation of this content. New White Paper from Claritas Rx Entitled "Quantifying Connection: Measuring Partner Impact and CRM ROI Across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback